Navigation Links
MAP Pharmaceuticals Reports Second Quarter of 2008 Financial Results
Date:8/12/2008

MOUNTAIN VIEW, Calif., Aug. 12 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the second quarter ended June 30, 2008.

The net loss for the second quarter ended June 30, 2008 was $16.5 million compared with $8.7 million during the same period in 2007. The net loss for the first six months of 2008 was $30.8 million compared to $15.3 million for the first six months of 2007. As of June 30, 2008, MAP Pharmaceuticals had cash, cash equivalents and short-term investments of $76.2 million.

2008 Year-to-date accomplishments

-- Clinical development

-- Initiated a Phase 3 clinical program to evaluate UDB for the

potential treatment of pediatric asthma.

-- Initiated a Phase 3 clinical program to evaluate MAP0004 for the

potential treatment of migraine, pursuant to a Special Protocol

Assessment with the U.S. Food and Drug Administration.

-- Announced positive results from a pharmacokinetic clinical trial

of UDB, demonstrating lower systemic drug exposure when compared

to the currently marketed conventional nebulized budesonide.

-- Demonstrated positive results from a Phase 2a clinical study

evaluating MAP0005 for the potential treatment of asthma and

chronic obstructive pulmonary disease (COPD).

-- Peer-reviewed presentations

-- Published positive results from a Phase 2 study evaluating the

safety, tolerability and pharmacokinetics of MAP0004 in adult

asthmatics in Current Medical Research and Opinion.

-- Published positive results from a Phase 1 study evaluating the

safety and pharmacokinetics of MAP0004 in adults in Headache.

-- Delivered over 15 oral and poster presentations related to UDB and

MAP0004 at annual scientific conferences including: American

Academy of Allergy Asthma & Immunology (AAAAI), American Academy

of Neurology (AAN), Respiratory Drug Delivery (RDD), American

Thoracic Society (ATS) and American Headache Society (AHS).

-- Corporate progress

-- Added seasoned industry veterans to the management team and board

of directors, including: Donald J. Kellerman, Pharm.D. to the

position of Senior Vice President, Clinical Development and

Medical Affairs; Marco F. Rosa to the position of Vice President

of Human Resources; and H. Ward Wolff to the board of directors

and audit committee.

-- Secured a $20 million working capital loan to repay the existing

working capital loan and for general corporate purposes.

-- Acquired proprietary drug particle formulation technology from

Telesso Technologies Limited, formerly Eiffel Technologies

Limited.

"We continue to make progress toward our goal of providing better medicines to patients, with clearly differentiated product benefits for undermet medical needs," said Timothy S. Nelson, President and Chief Executive Officer of MAP Pharmaceuticals. "With two product candidates now in Phase 3 studies, we remain focused on building the team, infrastructure and resources we need to advance MAP Pharmaceuticals through Phase 3 trials, toward commercializing products that address major market opportunities."

Second Quarter and Six Month Financial Results

Research and development expenses for the second quarter and six months ended June 30, 2008 were $13.0 million and $24.8 million, respectively, compared to $6.3 million and $10.8 million, respectively, for the same periods in 2007. The increase in research and development expenses for the three and six months ended June 30, 2008 as compared to the same periods in 2007 was primarily driven by an increase in clinical program expenses to support Phase 3 clinical programs initiated in 2008 for our two lead programs UDB and MAP0004, and an increase in personnel related expenses also related to the support of these clinical programs.

Sales, general and administrative expenses for the second quarter and six months ended June 30, 2008 were $3.2 million and $6.3 million, respectively, compared to $2.7 million and $4.5 million, respectively, for the same periods in 2007. The increase in sales, general and administrative expenses for the three months ended June 30, 2008 as compared to the same period in 2007 was primarily related to increases in personnel related expenses and stock-based compensation, partially offset by a decrease in non-recurring IPO expenses incurred in the prior year. The increase in sales, general and administrative expenses for the six months ended June 30, 2008 as compared to the same period in 2007 was primarily related to increases in personnel related expenses and stock-based compensation, and increased costs as a result of being a public company, partially offset by a decrease in non-recurring IPO expenses incurred in the prior year.

MAP Pharmaceuticals had cash, cash equivalents and short-term investments as of June 30, 2008 of $76.2 million, compared to $95.0 million as of December 31, 2007. In addition, for the second quarter ended June 30, 2008, non-cash share-based compensation and depreciation was approximately $1.5 million.

About MAP Pharmaceuticals, Inc.

MAP Pharmaceuticals develops and plans to commercialize new therapies for children and adults who suffer from chronic conditions that it believes are not adequately treated by currently available medicines. The company applies its proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. MAP Pharmaceuticals has two drug candidates in Phase 3 clinical trials. Unit Dose Budesonide is being developed for the potential treatment of pediatric asthma, and MAP0004 is being developed for the potential treatment of migraine. MAP Pharmaceuticals' pipeline also includes a drug candidate in early clinical development for the treatment of asthma and chronic obstructive pulmonary disease.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

Forward-Looking Statements

In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to our late stage clinical programs. Actual results may differ materially from current expectations based on risks and uncertainties affecting MAP Pharmaceuticals' business, including, without limitation, risks and uncertainties relating to the enrollment and conduct of clinical trials, as well as risks related to the failure to achieve favorable clinical outcomes and that our product candidates will not be approved for commercial use by the U.S. Food and Drug Administration. The reader is cautioned not to unduly rely on the forward-looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Additional information on potential factors that could affect MAP Pharmaceuticals' results and other risks and uncertainties are detailed in its Quarterly Report on Form 10-Q, filed with the SEC on May 14, 2008, and available at http://edgar.sec.gov .

CONTACT: Christopher Y. Chai, Chief Financial Officer, +1-650-386-3107 of MAP Pharmaceuticals, Inc., or Julio Cantre, media contact, +1-415-946-1055, of WeissComm Partners.

MAP PHARMACEUTICALS, INC.

(a development stage enterprise)

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

(Unaudited)

June 30, December 31,

2008 2007

Assets

Current assets:

Cash, cash equivalents and short-term

investments $76,185 $94,990

Other current assets 748 1,079

Total current assets 76,933 96,069

Property and equipment, net 5,637 4,183

Restricted cash 321 321

Other assets 36 122

Total assets $82,927 $100,695

Liabilities and stockholders' equity

Current liabilities:

Accounts payable and accrued expenses $9,308 $8,912

Current portion of long-term debt 3,048 3,820

Total current liabilities 12,356 12,732

Long-term debt, less current portion 17,478 6,357

Total liabilities 29,834 19,089

Total stockholders' equity 53,093 81,606

Total liabilities and stockholders'

equity $82,927 $100,695

MAP PHARMACEUTICALS, INC.

(a development stage enterprise)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except share and per share amounts)

(Unaudited)

Three Months Ended Six Months Ended

June 30, June 30,

2008 2007 2008 2007

Operating expenses:

Research and development $12,984 $6,316 $24,799 $10,833

Sales, general and

administrative 3,165 2,708 6,305 4,457

Total operating expenses 16,149 9,024 31,104 15,290

Loss from operations (16,149) (9,024) (31,104) (15,290)

Other income (expense),

net (308) 336 347 (58)

Net loss (16,457) (8,688) (30,757) (15,348)

Cumulative stock dividend

attributable to preferred

stockholders - (2,290) - (3,673)

Net loss attributable to

common stockholders $(16,457) $(10,978) $(30,757) $(19,021)

Net loss per share

attributable to common

stockholders, basic and

diluted $(0.81) $(14.29) $(1.52) $(25.11)

Weighted-average common

shares used in computing

net loss per share

attributable to common

stockholders, basic

and diluted 20,314,390 768,212 20,262,318 757,536


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Triax Pharmaceuticals Launches New Mid-Potency Corticosteroid Vehicle, Locoid Lotion 0.1%
2. ADVENTRX Pharmaceuticals Reports Second Quarter 2008 Financial Results and Business Update
3. Novis Pharmaceuticals Announces John W. Kilgour as Executive Vice-President of Sales & Marketing
4. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
5. Alseres Pharmaceuticals to Host 2008 Second Quarter Conference Call
6. Cipher Pharmaceuticals announces U.S. distribution and supply agreement with Ranbaxy for CIP-ISOTRETINOIN
7. Pacira Pharmaceuticals, Inc. Adds Experienced CFO James S. Scibetta to Leadership of the Organization
8. NUCRYST Pharmaceuticals to Release Second Quarter 2008 Financial Results on Tuesday, August 12, 2008
9. Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results
10. Handa Pharmaceuticals Announces Submission of its First-to-File ANDA for AstraZenecas SEROQUEL(R) XR
11. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... WI (PRWEB) , ... February 09, 2016 , ... ... Bergner’s, Boston Store, Carson’s, Elder-Beerman, Herberger’s and Younkers department stores, announced it has ... College of Wisconsin Cancer Center, Holden Comprehensive Cancer Center at the University of ...
(Date:2/9/2016)... ... , ... Two renowned photographers, Robert Caplin (New York, NY) and Peter Lockley ... 14-19, 2016, hosted by Four Seasons Resort Maui at Wailea as part of the ... 2015, the Maui Photo Expedition workshop will once again consist of on-location ...
(Date:2/9/2016)... ... February 09, 2016 , ... The Brain ... won. A team from 21st Century Medicine (21CM) ( http://www.21cm.com/ ), spearheaded ... delicate neural circuits of an intact rabbit brain for extremely long-term storage using ...
(Date:2/8/2016)... ... February 08, 2016 , ... Stephanie Hebert ... the beginning of a new charity campaign. As part of their ongoing community ... (CASA). In the belief that children deserve a voice, and in the spirit ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... and clothing, announced expansion into Canada to provide its range of unique and ... sales office in Quebec City that will provide bilingual customer service and marketing ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Feb. 8, 2016 Nueterra, the ... specialized in the development of equity partnerships ... it has divided its interests between two ... Capital will continue the founding company,s private ... operate a national system of integrated provider ...
(Date:2/8/2016)... MEMPHIS, Tenn. , Feb. 8, 2016  A ... Hospital scientists has discovered details of how the ... cells triggers a particularly aggressive form of acute lymphoblastic ... cells, in which genetic mutations trigger overproduction of immature ... --> The discoveries of the malfunction underlying the ...
(Date:2/8/2016)... PALO ALTO, Calif. , Feb. 8, 2016 /PRNewswire/ ... manufacturing, and Kodiak Sciences Inc., a biopharmaceutical company designing ... disease, announced today agreements for the clinical supply of ... material at multiple sites, including Slough (UK), Visp (CH) ... --> Retinal diseases, such as age-related macular ...
Breaking Medicine Technology: